Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
McKesson
Boehringer Ingelheim
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,799,331

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,799,331 protect, and when does it expire?

Patent 7,799,331 protects FLO-PRED and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 7,799,331
Title:Oral suspension of prednisolone acetate
Abstract: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
Inventor(s): Asotra; Satish (Brampton, CA), Gao; Shen (Botton, CA), Yacobi; Avraham (Englewood, NJ)
Assignee: Taro Pharmaceutical North America, Inc. (Grand Cayman, KY)
Application Number:11/457,197
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,799,331

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No   Start Trial   Start Trial Y TREATMENT OF ASTHMA   Start Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No   Start Trial   Start Trial Y TREATMENT OF ALLERGIC REACTIONS   Start Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No   Start Trial   Start Trial Y TREATMENT OF ALLERGIC REACTIONS   Start Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No   Start Trial   Start Trial Y TREATMENT OF ASTHMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,799,331

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006278620   Start Trial
Canada 2616112   Start Trial
China 101247786   Start Trial
European Patent Office 1909798   Start Trial
European Patent Office 2630951   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Dow
Boehringer Ingelheim
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.